Recipient of federal assistance · CAMBRIDGE, MA

EMMUNE INC

EMMUNE INC received $596.8K in federal grants and other assistance in FY2026, on 4 actions, −81% vs FY2025. It has no federal contracts in the loaded years. Since FY2021: $13.5M. Its largest awarding agency was National Institutes of Health ($596.8K).

Assistance · FY2026
$596.8K
New awards
2
Actions
4
Since FY2021
$13.5M
UEI
N65ZDYUGWAH8
Location
CAMBRIDGE, MA
Businesses
Open in the explorerFederal grants & assistance

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

Assistance by fiscal year

  1. 1.2MFY2021
  2. 3.2MFY2022
  3. 3.3MFY2023
  4. 2MFY2024
  5. 3.2MFY2025
  6. 596.8KFY2026

By type

  1. Grants$596.8K100%

Top programs · Awarding agencies

Obligations in FY2026.

Top programs

  1. 93.837 · Cardiovascular Diseases Research$299.7K50%
  2. 93.855 · Allergy and Infectious Diseases Research$297.1K50%

Awarding agencies

  1. National Institutes of Health$596.8K100%
    Department of Health and Human Services

Largest awards

  1. NON-VIRAL GENE THERAPY WITH ECD4-IG - ABSTRACT WE ARE DEVELOPING NON-VIRAL GENE THERAPY WITH ECD4-IG AS A PRACTICAL APPROACH FOR…$917.3K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Jun 17, 2025 – Dec 11, 2025· R56AI189343
  2. IND-ENABLING STUDIES FOR ECD4-IG AS A LONG-ACTING RECOMBINANT PROTEIN THERAPEUTIC - ABSTRACT THIS FASTTRACK SBIR GRANT WILL SUPPORT…$300K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· May 9, 2025 – Mar 2, 2026· R43AI191927
  3. NON-VIRAL GENE THERAPY TO TREAT AND PREVENT ATHEROSCLEROSIS - ABSTRACT ADENO-ASSOCIATED VIRUS (AAV) VECTORS CAN INTRODUCE A NON-INTEGRATING…$299.7K
    93.837 · Cardiovascular Diseases Research· National Institutes of Health· Project grant· Aug 24, 2026 – Aug 24, 2026· R44HL184837
  4. PK, TOLERABILITY, AND TOXICOLOGY STUDIES FOR ECD4-IG AS A LONG-ACTING RECOMBINANT PROTEIN THERAPEUTIC - ABSTRACT THIS FASTTRACK SBIR GRANT…$299.4K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Jul 24, 2026 – Jul 24, 2026· R44AI197364

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026 · FY2021–FY2026.